Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular cacinoma

Cancer

Volumn 98, Issue 1, 2003, Pages 119-127

  Pan, Hung Wei ^a,b   Ou, Yueh Hsing ^b   Peng, Shian Yang ^c   Liu, Shu Hsian ^a   Lai, Po Lin ^a   Lee, Po Hwaung ^a   Sheu, Jin Chuan ^a   Chen, Chi Ling ^d   Hsu, Hey Chi ^a,e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Early tumor recurrence; Hepatocellular carcinoma; Metastasis; Osteopontin; Portal vein invasion; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; MESSENGER RNA; MUTANT PROTEIN; OSTEOPONTIN; PROTEIN P53;

ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NORTHERN BLOTTING; PORTAL VEIN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, NORTHERN; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OSTEOPONTIN; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SIALOGLYCOPROTEINS; SURVIVAL ANALYSIS;

EID: 0038340658     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11487     Document Type: Article

References (49)

1. Denhardt DT, Guo XJ. Osteopontin: a protein with diverse functions. FASEB J. 1993;7:1475-1482.
2. Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem. 1998;30/31 (Suppl):92-102.
3. 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest. 1995;95:713-724.
4. Xuan JW, Hota C, Shigeyama Y, D'Errico JA, Somerman MJ, Chambers AF. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem. 1995;57:680-690.
5. Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol. 1993;13:225-246.
6. 3 integrin-induced endothelial cell survival. J Cell Biol. 1998;141:1083-1093.
7. Hwang SM, Lopez CA, Heck DE, et al. Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem. 1994;269:711-715.
8. Young MF, Kerr JM, Termine JD, et al. cDNA cloning. mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics. 1990;7:491-502.
9. Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res. 1989;9:1291-1299.
10. Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science. 1986;233:467-470.
11. 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci U S A. 1992;89:1557-1561.
12. Senger DR, Asch BB, Smith BD, Perruzzi CA, Dvorak HF. A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature. 1983;302:714-715.
13. Craig AM, Bowden GT, Chambers AF, et al. Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J Cancer. 1990;46:133-137.
14. Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene. 1996;13:97-104.
15. Behrend EI, Craig AM, Wioson SM, Denhardt DT, Chambers AF. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res. 1994;54:832-837.
16. Gardner HAR, Berse B, Senger DR. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumor-igenicity of transformed Rat 1 fibroblasts. Oncogene. 1994;9:2321-2326.
17. Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol. 1994;145:610-623.
18. Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 1998;79:127-132.
19. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer. 1996;15:311-323.
20. Gillespie MT, Thomas RJ, Pu ZY, Zhou H, Martin TJ, Findlay DM. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer. 1997;73:812-815.
21. Casson AG, Wilson SM, McCart JA, et al. ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer. 1997;72:739-745.
22. Oates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis. 1997;17:1-15.
23. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. β-Catenin mutations are associated with a subset of low stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol. 2000;157:763-770.
24. Liu SH, Lin CY, Peng SY, et al. Downregulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. Am J Pathol. 2002;160:1831-1837.
25. Hsu HC, Wu TT, Wu MZ, Sheu JC, Lee CS, Chen DS. Tumor invasiveness and prognosis in resected hepatocellular carcinoma: clinical and pathogenetic implications. Cancer. 1988;61:2095-2099.
26. Hsu HC, Chiou TJ, Chen ZY, Lee CS, Lee PH, Peng SY. Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules. Hepatology. 1991;13:923-928.
27. Peng SY, Lai PL, Chu JS, et al. Expression and hypomethylation of alpha-fetoprotein gene in unicentric and multicentric human hepatocellular carcinomas. Hepatology. 1993;17:35-41.
28. Hsu HC, Tseng HJ, Lai PL, Lee PH, Peng SY. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res. 1993;53:4691-4694.
29. Kobayashi T, Kubota K, Takayama T, Makuuchi M. Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg. 2001;181:284-288.
30. Hu RH, Lee PH, Yu SC, et al. Surgical resection of recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. Surgery. 1996;120:23-29.
31. Nagasue N, Uchida M, Makino Y, et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology. 1993:105:488-494.
32. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500-507.
33. Sobin LH, Wittekind C, eds. TNM classification of malignant tumors, 5th edition. New York: John Wiley & Sons, 1997:74-77.
34. Vincent S, Marty L, Fort P. S26 ribosomal protein RNA: an invariant control for gene regulation experiments in eukaryotic cells and tissues. Nucleic Acids Res. 1993;21:1498.
35. Hsu HC, Peng SY, Lai PL, Chu JS, Lee PH. Mutations of p53 gene in hepatocellular carcinoma (HCC) correlate with tumor progression and patient prognosis: a study of 138 patients with unifocal HCC. Int J Oncol. 1994;4:1341-1347.
36. Rittling SR, Novick KE. Osteopontin expression in mammary gland development and tumorigenesis. Cell Growth Differ. 1997;8:1061-1069.
37. Sharp JA, Sung V, Slavin J, Thompson EW, Henderson MA. Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. Lab Invest. 1999;79:869-877.
38. Tuck AB, Arsenault DM, O'Malley FP, et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene. 1999;18:4237-4246.
39. Tuck AB, O'Malley FP, Singhal H, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer. 1998;79:502-508.
40. Senger DR, Perruzzi CA. Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim Biophys Acta. 1996;1314:13-24.
41. Thalmann GN, Sikes RA, Devoll RE, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res. 1999;5:2271-2277.
42. Hart IR, Saini A. Biology of tumor metastasis. Lancet. 1992;339:1453-1457.
43. Stetler-Stevenson WG, Liotta LA, Kleiner DE. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993;7:1434-1441.
44. El-Tanani M, Barraclough R, Wilkinson MC, Rudland PS. Metastasis-inducing DNA regulates the expression of the osteopontin gene by binding the transcription factor tcf-4. Cancer Res. 2001;61:5619-5629.
45. Medico E, Gentile A, Lo Celso C, et al. Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res. 2001;61:5861-5868.
46. Shimada M, Takenaka K, Taguchi K, et al. Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg. 1998;227:80-85.
47. Izumi R, Shimizu K, Ii T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology. 1994;106:720-727.
48. Ouchi K, Sugawara T, Fujiya T, et al. Prediction of recurrence and extratumor spread of hepatocellular carcinoma following resection. J Surg Oncol. 2000;75(Suppl):241-245.
49. Nagasue N, Ono T, Yamanoi A, et al. Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis. Br J Surg. 2001;88:515-522.